C3 Jian has raised $30 million in equity financing, which will be used to conduct clinical trials of its caries-fighting peptide drug.
The company plans to file a new drug application with the U.S. Food and Drug Administration in April for the drug, C16G2. The financing will also be used to support the development, manufacturing, and clinical testing of a handheld diagnostic product related to C16G2, according to C3 Jian.
The company will also invest in its new proprietary peptide products, which are based on its platform technology. C3 Jian is the licensee of patents covering a cell-signaling platform technology from the University of California.
C3 Jian has used the platform to identify a variety of drugs, including peptides that could remineralize teeth, as well as promote hair and nail growth, the company said. The company maintains an intellectual property portfolio with more than 70 patents issued and pending worldwide.
C3 Jian will move into a biotechnology facility in Marina del Rey, CA, in May.
.DpIowD0Qsf.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20roland%20240910.waNaqlRrsD.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
